Positive recommendation based on phase III INAVO120 data showing ItovebiTM (inavolisib) in combination with palbociclib and ...

Itovebi (inavolisib) has been dealt a boost after the drug demonstrated further positive overall survival (OS) data in a ...

Basel: Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

Roche, hoping to carve out a standard-of-care spot for its PI3K inhibitor Itovebi, now has another leg to stand on with new ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said that an advisory panel of the European Medicines Agency (EMA), endorsed its Itovebi ...

Swiss healthcare company Roche (RHHBY) on Friday said that the European Medicines Agency’s Committee for Medicinal Products ...

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly ...

Who doesn’t love a comeback story? Certainly not GSK, which has found a way to resuscitate its cancer treatment Blenrep as a ...